Paratek Withdraws European Marketing Authorization Application for Oral and Intravenous NUZYRA in Skin Infections and Pneumonia
October 17, 2019 16:05 ET
|
Paratek Pharmaceuticals
Application approvable by European Medicine Agency (EMA) for skin infections based on two Phase 3 studiesEMA requesting second study in CABP to meet regulatory standards of two Phase 3 studiesCompany...
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
October 01, 2019 16:30 ET
|
Paratek Pharmaceuticals
BOSTON, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...
Paratek Pharmaceuticals Presenting New Data from NUZYRA® (Omadacycline) Development Program at IDWeek 2019
September 25, 2019 08:00 ET
|
Paratek Pharmaceuticals
BOSTON, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...
Paratek Mourns Passing of Co-founder Dr. Stuart Levy
September 09, 2019 08:00 ET
|
Paratek Pharmaceuticals
BOSTON, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) mourns the loss of Stuart Levy, M.D., who passed way last week. Dr. Levy co-founded the company more than two...
Paratek Pharmaceuticals to Present at the 21st Annual H.C. Wainwright Global Investment Conference
September 04, 2019 08:00 ET
|
Paratek Pharmaceuticals
BOSTON, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
September 03, 2019 16:05 ET
|
Paratek Pharmaceuticals
BOSTON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...
The Lancet Infectious Diseases Publishes Results from Paratek’s Phase 3 Oral only Dosing Study of NUZYRA® (omadacycline) for Skin Infections
August 30, 2019 08:00 ET
|
Paratek Pharmaceuticals
BOSTON, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...
Paratek Pharmaceuticals to Present at Robert W. Baird’s 2019 Global Healthcare Conference
August 26, 2019 16:05 ET
|
Paratek Pharmaceuticals
BOSTON, Aug. 26, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...
Paratek Pharmaceuticals Generates Net Revenues of $2.0 Million in the Second Quarter of 2019
August 06, 2019 16:05 ET
|
Paratek Pharmaceuticals
-- NUZYRA® (omadacycline) Net Sales increased 26% to $1.7 Million in the Second Quarter of 2019 -- -- Over 50% of Commercial Lives in U.S. now have Access to NUZYRA -- --...
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
August 01, 2019 16:05 ET
|
Paratek Pharmaceuticals
BOSTON, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...